Morphiex Biotherapeutics | Morphiex’s lead drug, MBT-001 inhibits tumor growth and metastasis in triple-negative breast cancer.
476
post-template-default,single,single-post,postid-476,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Morphiex’s lead drug, MBT-001 inhibits tumor growth and metastasis in triple-negative breast cancer.

Morphiex is excited to announce our lead drug, MBT-001 was recently published in Breast Cancer Research and Treatment. In summary, MBT-001 inhibited tumor growth and metastasis alone and in combination with chemotherapy.

https://www.ncbi.nlm.nih.gov/pubmed/30056566



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn